In March 2025, the US biosimilars market will celebrate ten years since the first biosimilar received approval from the US Food and Drug Administration, under the Biologics Price Competition and Innovation Act framework that was first introduced back in 2010.
Sandoz’s Zarxio (filgrastim-sndz) – approved in March 2015 and launched later that year – was the forerunner for all of the biosimilar approvals that followed, with the current total number...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?